Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are the standard of care for non–small cell lung cancer (NSCLC) patients with EGFR exon 19 deletion and L858R mutations. However, no EGFR TKI has been approved for NSCLC patients harboring insertion mutations in EGFR exon...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhi, Xiaoyu, Luo, Jiancheng, Li, Weiwei, Wang, Jinliang, Wang, Yuying, Cai, Yi, Yan, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573166/
https://www.ncbi.nlm.nih.gov/pubmed/34760695
http://dx.doi.org/10.3389/fonc.2021.733276

Ejemplares similares

Ejemplares similares